ATryn (antithrombin) / LFB SA, Knight Therap - LARVOL DELTA

Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis (clinicaltrials.gov) - P2; N=25; Terminated; Sponsor: LEO Pharma; N=200 ➔ 25

Clinical • Enrollment change • Infectious Disease • Septic Shock • IL6

Antithrombin Dose Optimization in Extracorporeal Membrane Oxygenation in Infants. (PubMed, ASAIO J) - "We conducted a retrospective review of patients <1 year of age who received recombinant AT (ATryn) while on UFH and ECMO between January 1, 2010 and December 31, 2017...Postdose levels were best predicted when using an equation that included desired change in the AT level from baseline, the patient's weight, and added weight from the volume of the ECMO circuit (r2 = 0.427). Prospective studies are needed to evaluate optimal dosing strategies, safety, and efficacy of AT in this population."

Journal

Understanding "Heparin Resistance" in Cardiac Surgery (clinicaltrials.gov) - P1; N=504; Completed; Sponsor: Massachusetts General Hospital; Phase classification: P=N/A ➔ P1

Phase classification • Biosimilar • Immunology

In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices. (PubMed, J Thorac Cardiovasc Surg) - "The EVAHEART left ventricular assist device caused less hemolysis, resulted in lower coagulation activation, and provided better preservation of von Willebrand factor functional activity compared with the HeartMate 3 device. These findings prove that left ventricular assist device design plays a major role in minimizing blood damage during left ventricular assist device support."

Journal • Preclinical

Non cirrhotic portal hypertension in myeloproliferative disease: left and right sided component of portal hypertension (APDW 2019) - "8/9 patients underwent endoscopic therapy for varices and were given prophylaxis with carvedilol. Out of 9 patients 4(44.4%) each had polycythemia-rubra-vera(PRV) and myelofibrosis while 1 had essential thrombocytosis. Median age was 50 +_ 7 yrs with 8 male and 1 female patient. 5(55.5%) presented with symptomatic splenomegaly,1(11.1%) with ascites and 3(33%) with GI bleed and comprised of 64.3 % in PRV."

F2